Cue Health Inc. (NASDAQ:HLTH – Get Rating) insider Clint Sever sold 19,215 shares of the company’s stock in a transaction on Tuesday, September 27th. The stock was sold at an average price of $2.94, for a total value of $56,492.10. Following the transaction, the insider now directly owns 3,950,280 shares in the company, valued at approximately $11,613,823.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Clint Sever also recently made the following trade(s):
- On Thursday, September 29th, Clint Sever sold 19,290 shares of Cue Health stock. The shares were sold at an average price of $2.94, for a total value of $56,712.60.
- On Wednesday, September 14th, Clint Sever sold 26,664 shares of Cue Health stock. The shares were sold at an average price of $3.58, for a total value of $95,457.12.
- On Wednesday, August 17th, Clint Sever sold 26,664 shares of Cue Health stock. The shares were sold at an average price of $4.32, for a total value of $115,188.48.
- On Wednesday, August 3rd, Clint Sever sold 26,664 shares of Cue Health stock. The shares were sold at an average price of $3.58, for a total value of $95,457.12.
- On Thursday, July 21st, Clint Sever sold 26,664 shares of Cue Health stock. The shares were sold at an average price of $3.33, for a total value of $88,791.12.
- On Tuesday, July 19th, Clint Sever sold 26,664 shares of Cue Health stock. The shares were sold at an average price of $3.49, for a total value of $93,057.36.
Cue Health Stock Performance
NASDAQ HLTH traded down $0.13 during trading hours on Thursday, hitting $2.93. 271,846 shares of the company’s stock were exchanged, compared to its average volume of 747,240. The business’s 50 day moving average is $3.60 and its 200-day moving average is $4.84. Cue Health Inc. has a 12-month low of $2.75 and a 12-month high of $16.20. The firm has a market capitalization of $434.09 million and a P/E ratio of -9.77.
Cue Health (NASDAQ:HLTH – Get Rating) last released its quarterly earnings data on Wednesday, August 10th. The company reported ($0.37) EPS for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.13. The company had revenue of $87.70 million for the quarter, compared to the consensus estimate of $52.54 million. Cue Health had a positive return on equity of 5.50% and a negative net margin of 6.24%. As a group, equities research analysts anticipate that Cue Health Inc. will post -1.31 EPS for the current fiscal year.
Analysts Set New Price Targets
A number of analysts recently commented on the company. Cowen decreased their price objective on Cue Health to $9.00 in a research note on Monday, August 15th. BTIG Research decreased their price objective on Cue Health to $9.00 in a research note on Monday, August 15th. Finally, Morgan Stanley reduced their target price on Cue Health from $10.00 to $8.00 and set an “equal weight” rating on the stock in a research report on Thursday, August 11th.
Hedge Funds Weigh In On Cue Health
A number of large investors have recently modified their holdings of HLTH. ProShare Advisors LLC purchased a new position in shares of Cue Health in the 2nd quarter worth about $38,000. Legal & General Group Plc raised its holdings in shares of Cue Health by 813.8% in the 2nd quarter. Legal & General Group Plc now owns 12,355 shares of the company’s stock worth $39,000 after purchasing an additional 11,003 shares during the period. Clay Northam Wealth Management LLC purchased a new position in shares of Cue Health in the 2nd quarter worth about $44,000. AMG National Trust Bank purchased a new position in shares of Cue Health in the 2nd quarter worth about $46,000. Finally, US Bancorp DE purchased a new position in shares of Cue Health in the 2nd quarter worth about $49,000. 37.87% of the stock is currently owned by hedge funds and other institutional investors.
Cue Health Company Profile
Cue Health Inc, a healthcare technology company, designs and develops diagnostic platform for diagnostic tests for individuals, enterprises, healthcare providers and payors, and public health agencies. The company offers Cue Integrated Care platform comprising hardware and software components, such as Cue Health Monitoring System consisting of Cue Reader, a portable and reusable reader, Cue Cartridge, a single-use test cartridge, and Cue Wand, a sample collection wand; Cue Data and Innovation Layer, a solution with cloud-based data and analytics capability; Cue Virtual Care Delivery Apps, which include Cue Health App and Cue Enterprise Dashboard; and Cue Ecosystem Integrations and Apps, a solution that allows integrations with third-party applications and sensors.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cue Health, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Cue Health wasn’t on the list.
While Cue Health currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.
Source: marketbeat.com
